Casi Pharmaceuticals announced the administration of the first dose of FOLOTYN to a patient in China. This remarks a pivotal step in CASI‘s commitment to addressing critical medical needs in peripheral T-cell lymphoma in China market.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
